Pharmaceutical Preparation Manufacturing in FY2024 (NAICS 325412)

NAICS 325412 × FY2024 is a pharma-mfg join, not a dose list

This page is a join: Pharmaceutical Preparation Manufacturing and fiscal year 2024. $29,736,814,484.92 is the obligation sum USAspending.gov attributes to NAICS 325412 in that fiscal year on the yearlyTrend series. It is not every federal dollar in FY2024, not Pharmaceutical Preparation Manufacturing’s lifetime book restated as a single year, and not an outlay register. NAICS 325412 is the industry parent. FY2024 federal spending is the year parent. Correlation is not causation.

The industry extract totals $59,825,795,303.53. FY2024’s $29,736,814,484.92 is the year slice of that book, about 49.7%. Remaining industry dollars sit in other fiscal years on the same NAICS, not inside this join. 51,311 is the industry-wide award count in this extract, not a FY2024 action count. Do not divide $29,736,814,484.92 by 51,311 and call the result a typical FY2024 award. Unique recipients are unpublished. This page will not invent contractors. FEC contribution tables do not fund these USAspending obligations. This page will not invent drug names, NDC counts, or contractors. About 49.7% of the industry extract sits in FY2024; the rest sits in other years on the same NAICS.

Pharmaceutical Preparation Manufacturing as a NAICS label

USAspending labels industry 325412 as Pharmaceutical Preparation Manufacturing. That code produced $29,736,814,484.92 when filtered to FY2024. The industry hub does not require a FY2024 filter. The fiscal-year hub does not require NAICS 325412. Only this tie applies both filters. The packet does not split vaccines from small-molecule folklore, or contract from assistance.

SpendingVault does not grade Pharmaceutical Preparation Manufacturing on output, headcount, or policy. $29,736,814,484.92 is an obligation sum, not a verdict. Other chemical NAICS codes remain outside this cell even when the work sounds adjacent. Open NAICS 325412 for the industry rollup without the year filter, FY2024 federal spending for the year rollup without the industry filter, All industries for the NAICS index, and All spending ties for other pairs.

What FY2024 contributes on this series

Fiscal year 2024 on this join is a USAspending yearlyTrend bucket, not a claim that every obligated dollar was performed in calendar 2024. Awards can list FY2024 while performance stretches across adjacent years. FY figures can be incomplete for a current year; this snapshot reports $29,736,814,484.92 as given. Other fiscal years for NAICS 325412 belong on those ties.

FY2024 federal spending shows how Pharmaceutical Preparation Manufacturing sits beside other industries in the same year extract. $29,736,814,484.92 is one industry-year column, not the year table. Quoting it as all of FY2024 would drop every other NAICS. The 49.7% industry share describes this join, not a ranking of industries as winners or losers. A 49.7% year share is a near-even split of the published 325412 book, not a ranking of manufacturers.

51,311 is the industry parent count

51,311 awards describe the Pharmaceutical Preparation Manufacturing extract, not the FY2024 slice alone. Mixing that count with $29,736,814,484.92 invents a per-award FY figure the packet does not publish. Treat 51,311 as the industry parent’s action count. Modifications can add rows on the parent. This cell is not a dose census, not a named-manufacturer roster, and not a named-prime file.

Obligations versus doses already shipped

An obligation is a recorded commitment. An outlay is a payment from the Treasury. $29,736,814,484.92 is the commitment figure for Pharmaceutical Preparation Manufacturing in FY2024. This packet has no outlay total, so none is invented. Citing the figure as cash already spent over-reads the field. Keep both sides in the citation: Pharmaceutical Preparation Manufacturing (NAICS 325412) and FY2024.

FDA and agency pharmacy ledgers answer other questions. They are not the source of this cell. If a chart mixes commercial activity with NAICS 325412 in FY2024, the chart has left the federal award series.

How to cite the 325412 × FY2024 pair

Cite: Pharmaceutical Preparation Manufacturing (NAICS 325412) obligated $29,736,814,484.92 in FY2024, per USAspending.gov yearlyTrend. Keep both keys. Keep the word obligations. Prefer NAICS 325412 and FY2024 federal spending when live tables move. None of those links convert this cell into a dose census, into a FY2024 award census this packet omits, or into a contractor list. Later bulk files can move both the FY2024 dollars and the industry $59,825,795,303.53 parent; quote the live hubs when the overlay and this snapshot diverge. All spending ties lists other industry-by-year pairs on the same obligation metric.

Questions

How much Pharmaceutical Preparation Manufacturing spending is in FY2024?

USAspending.gov records $29,736,814,484.92 in NAICS 325412 obligations for fiscal year 2024. That is an industry × year join, not an outlay and not all of FY2024 federal spending. The slice is about 49.7% of the industry’s $59,825,795,303.53 extract total.

Does 51,311 awards mean 51,311 drugs in FY2024?

No. 51,311 is the industry-wide award-action count in this extract, not a FY2024-only row total and not a product count. Unique recipients are unpublished. Do not divide $29,736,814,484.92 by that count.

Is $29,736,814,484.92 cash already paid?

No. Obligations are commitments recorded on USAspending.gov awards. Outlays are a different concept and are not this packet’s headline. FY figures can be incomplete. Prefer the live industry and year hubs if the tables moved.

Where are the live NAICS 325412 and FY2024 tables?

NAICS 325412 is the industry parent. FY2024 federal spending is the year parent. All industries is the NAICS index. All spending ties lists other pairs. This page quotes 325412 × FY2024 at $29,736,814,484.92.